# Where to Inject Peptides Injection site is not one rule. It is three separate decisions: - **Route:** SubQ, IM, intranasal, oral, topical, or IV. - **Site:** abdomen, thigh, upper arm, injury-adjacent tissue, or an IM muscle. - **Diluent:** standard BAC water, BAC water with Sodium Chloride (NaCl), or buffered NAD+ solvent. Most peptides enter circulation quickly after subcutaneous injection. That does not make site irrelevant. The tissue around the needle sees a brief high-concentration exposure before the compound dilutes through the bloodstream. For systemic peptides, that local spike does not matter much. For injury and inflammation peptides, it can matter because the target tissue is nearby. For sting-prone compounds, the bigger issue is often the solution itself. --- ## At a Glance | Compound / group | Default route and site | Site logic | Diluent note | |-----------------------------------------------|-------------------------------------------|------------------------------------------------------|--------------------------------------| | **Semaglutide / Tirzepatide / Retatrutide** | SubQ abdomen, thigh, or upper arm | Systemic appetite and metabolic signaling | Standard product directions | | **BPC-157** | SubQ near injury when practical | Local first-pass exposure may help accessible injury | Standard BAC water | | **TB-4 / TB-500** | SubQ near injury; IM only if trained | Local concentration matters more for injury bolus | Standard BAC water | | **KPV** | SubQ near inflamed area, or abdomen | Targets immune cells around inflammation | Standard BAC water | | **GHK-Cu** | SubQ abdomen or thigh | Systemic skin and matrix signal | Standard BAC water | | **GLOW / KLOW premix** | SubQ abdomen or thigh | Premixed injectable skin-quality cocktails | Use the vial directions | | **NAD+** | IM preferred; SubQ acceptable if split | Route matters more than exact site | Pre-buffered when available; NaCl affects tonicity, not acidity | | **MOTS-c** | SubQ abdomen or thigh | Systemic metabolic signal; local reactions common | Diluent choice is formulation-specific; no direct comparison | | **SS-31** | SubQ abdomen or thigh | Systemic mitochondrial signal; local reactions common | MRGPRX2 mechanism is direct; NaCl benefit remains untested | | **L-Carnitine / Glutathione** | IM commonly preferred | Volume and tolerability drive route | Follow product directions | | **Tesamorelin / Sermorelin / Ipamorelin** | SubQ abdomen, often PM fasted | Pituitary GH pulse; no local target | Follow product or pharmacy diluent instructions | | **Semax / Selank / VIP** | SubQ if injecting; intranasal as option | CNS use often favors nasal delivery | Standard BAC water if injectable | --- ## The Basic Rule For most at-home peptide users, the default injection site is subcutaneous fat in the abdomen or outer thigh. Stay at least 2 inches away from the belly button, avoid bruised or irritated skin, and rotate sites by at least 2 cm. Use this default for GLP-1s, GHK-Cu, GLOW/KLOW, most GH peptides, MOTS-c, SS-31, Semax/Selank if injectable, and general systemic protocols. Move away from the default only when the compound gives you a reason: **Injury-adjacent:** BPC-157, TB-4, TB-500, and KPV can be placed near the injured or inflamed area when the target is easy to reach. Think lateral knee tissue, Achilles-adjacent fat pad, shoulder/deltoid-adjacent fat, or elbow-adjacent subcutaneous tissue. Do not inject directly into tendons, ligaments, joints, or deep spine/hip structures without clinical training. **IM-first:** NAD+ is usually better as IM. L-Carnitine and glutathione are also commonly run IM because dose volume and local comfort matter. SubQ can still work for NAD+, but split it into smaller injections. **Non-injection route:** Semax, Selank, and VIP often have intranasal use cases. Oral routes are separate decisions for compounds like KPV, BPC-157 PDA, 5-Amino-1MQ, L-Carnitine, glutathione, and NAD+ precursors. --- ## What Syringe to Use for Peptide Injections For most SubQ peptide injections, PeptideFox suggests a **29–31 gauge, 1/2-inch insulin syringe**. The FDA-approved EGRIFTA SV kit uses a 1/2-inch, 30-gauge injection needle, which sits inside that range. Needle length matters as much as gauge: leaving the tip too close to the skin can turn an intended SubQ injection into a shallow intradermal injection.²⁵ ²⁶ If an intended SubQ injection is left too shallow, the dose is deposited intradermally. Skin mast cells can contribute to a wheal-and-flare response for MRGPRX2-reactive compounds; the direct clinical evidence here is for elamipretide (SS-31), not every peptide. Injection depth, concentration, volume, speed, and solution pH or tonicity can all contribute to local reactions.²³ ²⁵ Use enough needle depth to reach true subcutaneous fat, inject slowly, and rotate sites. Body composition changes the appropriate angle and technique, so anyone who is very lean or unsure of the tissue depth should have a clinician demonstrate it. IM injections use different syringes and technique; the common peptide default above should not be applied to IM NAD+, L-carnitine, or glutathione. --- ## How Peptides Move After Injection Subcutaneous injection does not trap a peptide in one spot. Small peptides and many peptide-like drugs diffuse into local capillaries and lymphatic flow, then distribute systemically. Injection site can still change the first few minutes of exposure because the area around the needle sees the highest concentration before dilution (subcutaneous absorption¹, injection-site PK²). The practical question is not "does it stay local?" It does not. The question is: **Does this compound need the local concentration spike, or is systemic exposure enough?** That answer changes by compound. ## GLP-1s: Semaglutide, Tirzepatide, Retatrutide Use SubQ abdomen, front/outer thigh, or back of the upper arm if someone else is injecting. Rotate sites. GLP-1s work through systemic signaling: brain appetite circuits, gut motility, pancreas, liver-facing metabolic changes, and for tirzepatide/retatrutide, additional incretin and glucagon-receptor effects. The injection site is not the target. Abdomen may absorb a little faster than thigh for some drugs, but the main user-level rule is consistency and rotation. For reconstituted GLP-1s, keep the injection separate from every other peptide. GLP-1 titration depends on clean tracking: nausea, constipation, heart rate, appetite collapse, fatigue, and sleep changes should be attributable to one compound. Related: [Semaglutide guide](/content/semaglutide) · [Tirzepatide guide](/content/tirzepatide) · [Retatrutide guide](/content/retatrutide) --- ## BPC-157 Use SubQ near the injury when the area is practical and superficial. Use abdomen or thigh when the injury is deep, awkward, or unsafe to approach. BPC-157 is systemic, but it has a stronger case for injury-adjacent injection than most peptides. The reason is concentration. In vitro tendon and repair-cell work often uses higher sustained concentrations than a distant systemic SubQ shot is likely to create in muscle or tendon tissue (BPC-157 PK and tissue distribution⁶, tendon fibroblast studies⁷ ⁸). Local SubQ placement gives the nearby tissue a brief high-concentration pass before systemic dilution. That is a practical bias, not a proven route comparison. No published human study has directly compared near-injury SubQ BPC-157 against abdomen SubQ for the same injury. ### Common BPC-157 Sites **Knee:** SubQ on the medial or lateral side depending on the injury pattern. Stay in subcutaneous tissue; do not inject into the joint. **Shoulder:** SubQ into the deltoid-adjacent fat pad near the painful region. **Elbow:** SubQ near the medial or lateral epicondyle. Use shallow technique because the tissue is thin. **Achilles / ankle:** SubQ into tissue adjacent to the Achilles or ligament region. Do not inject directly into the tendon. **Back / spine / deep hip:** Use abdomen or thigh. Deep structures are not good at-home targets. Related: [BPC-157 guide](/content/bpc-157) · [Wolverine Stack](/content/wolverine-stack) --- ## TB-4 and TB-500 Use SubQ near the injury when practical. IM is an advanced option for trained users trying to reach a deep muscle target, but it is not the default for casual at-home use. This naming is messy. GLOW and KLOW usually contain **TB-4**, the full-length thymosin beta-4 peptide. Many injury protocols use a separate **TB-500/TB-4 bolus** at 2-4 mg, usually twice weekly. That bolus is the injury add-on; the small TB-4 amount inside GLOW/KLOW is a background tissue-support layer, not a full injury dose. TB-4/TB-500 is more concentration-dependent than GHK-Cu. The active actin-binding region helps repair cells migrate and organize structural proteins (TB-500 prodrug metabolism⁵). That kind of mechanism benefits from reaching enough local concentration. This is why injury protocols often place the injection near the injured area when the area is easy to access. Related: [TB-500 guide](/content/tb-500) · [Injury Recovery Protocol](/content/injury-recovery-peptide-protocol) --- ## KPV Use SubQ near the inflamed area when inflammation is local and accessible. Use abdomen when the target is systemic inflammation, gut inflammation, or a general immune-calming protocol. KPV is not a structural repair peptide. It works by calming immune signaling in cells that are driving inflammation (PepT1 and NF-kB mechanism²⁴). For a red, swollen, irritated tendon or post-procedure skin flare, local placement can make sense because the immune-cell traffic is concentrated there. For gut or systemic inflammation, local skin placement matters less. KPV also has oral use cases for gut-focused protocols. That is a route decision, not an injection-site decision. Related: [KPV guide](/content/kpv) · [Immune Peptide Protocol](/content/immune-peptide-protocol) --- ## GHK-Cu Use SubQ abdomen or thigh. Rotate sites. GHK-Cu does not need injury-adjacent placement for most protocols. It works at low concentrations and acts as a broad skin, collagen, and extracellular-matrix signal rather than as a local structural bolus (GHK-Cu gene expression and effective concentration⁴). Animal work also supports distant injection effects on wound and tissue repair (GHK-Cu systemic healing⁹). Use standard BAC water. GHK-Cu can sting, especially at higher concentration, but it is not the same problem as NAD+ acidity or SS-31/MOTS-c cationic welting. If the injection burns, the first fixes are more dilution, slower injection, and better site rotation, not default BAC water with NaCl. In custom stacks, keep GHK-Cu separate when compatibility is uncertain. Premixed GLOW/KLOW vials are a different situation: the compounds were lyophilized together as a finished blend. Related: [GHK-Cu guide](/content/ghk-cu-skin) --- ## GLOW and KLOW Use SubQ abdomen or thigh. Rotate sites. GLOW and KLOW are premixed lyophilized injectable cocktails: - **GLOW:** GHK-Cu + BPC-157 + TB-4 - **KLOW:** GHK-Cu + BPC-157 + TB-4 + KPV For standard skin-quality use, the cocktail itself is the protocol. Local targeting is not the goal. Injecting abdomen or thigh lets the blend distribute systemically for skin, connective tissue, and background repair support. For injury use, GLOW/KLOW may be a supportive background layer, but the injury-specific move is usually a separate TB-500/TB-4 bolus near the injury when practical. Do not treat the small TB-4 amount in a cosmetic cocktail as the same thing as a standalone injury bolus. Related: [GLOW & KLOW Protocol](/content/glow-klow-protocol) · [GLOW dosing](/tools/glow-dosage-calculator) · [KLOW dosing](/tools/klow-dosage-calculator) --- ## NAD+ Use IM as the preferred route. Use SubQ only if the dose is small enough to tolerate, or split it across multiple small SubQ injections. NAD+ is not a classic signaling peptide. It is a redox cofactor: cells use it to move electrons through energy metabolism, repair stress, and support mitochondrial work. The exact skin site matters less than tolerability and route. ### IM NAD+ Common IM sites include deltoid, vastus lateralis, and ventrogluteal muscle. IM usually handles NAD+ better because muscle can absorb the volume and acidity with less welting than shallow SubQ tissue. Inject slowly. NAD+ burn is often a speed and pH problem, not a sign the compound is "working harder." ### SubQ NAD+ SubQ is acceptable, especially at lower doses or when IM is not an option. Split larger doses into smaller injections. A single large SubQ bolus is where users most often get welts, burning, and lingering soreness. ### Diluent Some reconstituted NAD+ products are acidic. A pre-buffered product is preferable when available. If the product or dispensing pharmacy permits BAC water with Sodium Chloride (NaCl), the salt addresses tonicity rather than acidity. Slow injection and smaller volume still matter.²⁵ ³¹ ³² Related: [NAD+ guide](/content/nad-guide) --- ## MOTS-c and SS-31 Use SubQ abdomen or thigh. Rotate aggressively. Consider smaller injection volumes and BAC water with NaCl. MOTS-c and SS-31 are two of the more common injection-site offenders in protocol use. The issue is not just "bad BAC water." SS-31 has direct clinical evidence for mast-cell activation through MRGPRX2. Applying that mechanism to MOTS-c is a formulation inference from its cationic profile and field reaction pattern, not a direct MOTS-c receptor study.²³ ²⁷ ²⁸ ³² ### What Users See **Wheal-and-flare:** itchy red bump or small welt at the injection site. This is usually local mast-cell activation where peptide concentration is highest. **Systemic flushing:** warmth or redness across face, neck, or chest. This can happen when exposure rises quickly or the user has a lower mast-cell threshold. **Allergic-pattern symptoms:** hives away from the injection site, facial swelling, throat tightness, or breathing changes. Stop and evaluate clinically. Do not assume this is normal peptide flushing. ### Comfort Strategy PeptideFox considers BAC water with Sodium Chloride (NaCl) for SS-31 and MOTS-c when the product or dispensing pharmacy permits it. NaCl changes tonicity and ionic strength, but no controlled diluent study has shown that it reduces welts for either peptide. Higher ionic strength can also increase aggregation risk in some peptide formulations. The 7–14-day refrigerated window is therefore a conservative PeptideFox protocol default unless the manufacturer or pharmacy supplies a different beyond-use date; it is not a compound-specific stability result.²⁹ ³⁰ ³¹ ³² Related: [MOTS-c guide](/content/mots-c) · [SS-31 guide](/content/ss-31) --- ## Tesamorelin, Sermorelin, and Ipamorelin Use SubQ abdomen. For GH-pulse protocols, dosing is often PM and fasted: at least 2 hours after food, and usually 60-90 minutes before sleep. GH peptides are not local repair injections. They reach the pituitary through circulation and trigger a growth-hormone pulse. Site choice is mainly about comfort and consistency. **Tesamorelin:** deeper SubQ and strict rotation matter because injection-site reactions are common in the human trial record (tesamorelin injection-site reactions¹⁹). For labeled EGRIFTA SV, follow the supplied sterile-water instructions. For a compounded product, any diluent change should follow the prescriber, pharmacy, or manufacturer rather than an inference that NaCl is universally better.²⁵ ²⁶ ³² **Sermorelin:** SubQ abdomen is standard. If histamine-type welts recur, a different diluent is a formulation-specific decision for the prescriber or pharmacy. Extending the cationic-ligand rationale to sermorelin is an inference, not a direct diluent-comparison result.²⁷ ²⁸ ³² **Ipamorelin:** SubQ abdomen is standard. Local reactions can still happen. If welts recur, a different diluent is a formulation-specific decision for the prescriber or pharmacy; no controlled comparison establishes NaCl as the better option.³² Related: [Tesamorelin guide](/content/tesamorelin) · [Sermorelin guide](/content/sermorelin) · [Ipamorelin guide](/content/ipamorelin) · [GH Secretagogue Comparison](/content/gh-secretagogue-comparison) --- ## Semax, Selank, and VIP If injecting, use SubQ abdomen or thigh. Intranasal is a separate route option, especially for CNS-focused use. Semax and Selank are often used for cognition, anxiety, neuroinflammation, and recovery. Intranasal delivery can be attractive because the target is the central nervous system. But if the user is asking where to inject them, the injection answer is simple: SubQ abdomen or thigh, rotate sites, standard BAC water unless the vial instructions say otherwise. For N-Acetyl Semax Amidate and N-Acetyl Selank Amidate, do not create a separate injection-site rule. These are stabilized versions of the same parent backbone. Dose and frequency may differ, but site logic is the same. Related: [Semax guide](/content/semax) · [Selank guide](/content/selank) --- ## Which Compounds Are Compatible in the Same Syringe? Keep this conservative. Mixed-vial compatibility is not the same thing as drawing separate vials into one syringe at home. **Usually reasonable:** BPC-157 + KPV. Add TB-4/TB-500 on TB days only if the protocol explicitly calls for that bolus and the injection-site reaction burden is low. **Premixed only:** GLOW and KLOW are already combined in the lyophilized vial. Inject the premix as supplied. Do not use their existence as permission to combine arbitrary separate GHK-Cu, BPC-157, KPV, and TB-4 vials in one syringe. **Keep separate:** NAD+, GLP-1s, SS-31, MOTS-c, GHK-Cu in custom stacks, L-Carnitine, glutathione, and any peptide where the diluent differs. **GH peptides:** Sermorelin + ipamorelin combinations are common as purpose-built blends. If they came as separate vials, treat co-injection as a compatibility decision, not an automatic rule. --- ## BAC Water, Sodium Chloride, Buffered NAD+, and Taurine Most peptides use standard bacteriostatic water. BAC water with NaCl is not a universal upgrade. It is a comfort tool for specific cases: **Use standard BAC water:** BPC-157, TB-4/TB-500, KPV, GHK-Cu, GLOW/KLOW unless the vial directions specify otherwise, most GLP-1s, Semax, and Selank. **Consider BAC water with NaCl:** SS-31, MOTS-c, sermorelin, and ipamorelin if welts are a real problem and the product or dispensing pharmacy permits it. The MRGPRX2 evidence is direct for SS-31; extending the same rationale to the other compounds is formulation inference.²³ ²⁷ ²⁸ ³² **For NAD+, separate buffering from tonicity:** Use a pre-buffered product when available. If product or pharmacy instructions permit BAC water with NaCl, the salt addresses tonicity—not acidity. NaCl alone does not make an acidic NAD+ product buffered. Do not add bicarbonate or salt manually.²⁵ ³¹ ³² **Keep taurine formulation-specific:** Some glutathione products or written protocols already include taurine. That is product-specific guidance, not controlled evidence that taurine broadly prevents welts. Do not add taurine manually to peptide vials.³² The basis is practical tolerability, not efficacy. NaCl changes tonicity and ionic strength; treating that as a way to reduce charge-driven irritation in specific cationic peptides is a formulation inference because no controlled diluent trial has tested it. Higher ionic strength can also increase aggregation risk in some peptide formulations. PeptideFox therefore uses a conservative 7–14-day refrigerated window unless the manufacturer or dispensing pharmacy provides a different beyond-use date.²⁹ ³⁰ ³¹ ³² --- ## FAQ ### What evidence compares injury-adjacent and abdominal peptide injection? For accessible injuries, it is the practical default for BPC-157, TB-4/TB-500, and KPV. It gives the target region a higher first-pass exposure before systemic dilution. But the human route-comparison study does not exist, so this should not be framed as proven superiority. ### Which injection sites are used for semaglutide? SubQ abdomen, thigh, or upper arm. Rotate sites. Keep semaglutide separate from every other compound. ### Which injection sites are used for tirzepatide? SubQ abdomen, thigh, or upper arm. Rotate sites. Keep it separate so side effects and dose response are easy to track. ### Which injection sites are used for retatrutide? SubQ abdomen, thigh, or upper arm. Rotate sites. Retatrutide titration is sensitive, so do not combine it in the same syringe with anything else. ### Where should GLOW peptide be injected? Inject GLOW SubQ in the abdomen or thigh and rotate sites. For standard skin-quality use, the premixed blend is intended to distribute systemically; it does not need to be injected near the face or another cosmetic target. For an injury protocol, a separate TB-4/TB-500 bolus may be placed near an accessible injury when the protocol calls for it, but the GLOW premix remains the background layer. ### Where should KLOW peptide be injected? Inject KLOW SubQ in the abdomen or thigh and rotate sites. The premixed blend is normally used systemically for skin and connective-tissue support. Do not inject it into a tendon, ligament, or joint; injury-adjacent placement is reserved for accessible subcutaneous tissue and protocol-specific bolus decisions. ### Which injection sites are used for NAD+? IM is preferred: deltoid, vastus lateralis, or ventrogluteal. SubQ is acceptable if the dose is split into smaller injections. Use a pre-buffered NAD+ product when possible; if product or pharmacy instructions permit BAC water with NaCl, treat it as a tonicity measure rather than a substitute for buffering. Inject slowly.²⁵ ³¹ ³² ### Which peptides are most often associated with injection-site reactions? SS-31, MOTS-c, and NAD+ are common offenders in protocol use. SS-31 has direct MRGPRX2 evidence; applying the same mechanism to MOTS-c is a formulation inference. For NAD+, product acidity, volume, and injection speed can contribute. GHK-Cu can sting, but it is usually handled with dilution and rotation rather than BAC water with NaCl as the default.²³ ²⁵ ³¹ ³² ### What syringe should I use for peptide injections? For most SubQ peptide injections, PeptideFox suggests a 29–31 gauge, 1/2-inch insulin syringe and enough depth to reach subcutaneous fat; the FDA-approved EGRIFTA SV kit uses a 1/2-inch, 30-gauge injection needle. An injection left too close to the skin can land intradermally and contribute to an itchy bump, stinging, redness, or a welt. IM needle selection depends on the site and body composition, and a qualified clinician should demonstrate IM technique.²⁵ ²⁶ ### What role does injection-site rotation play? Yes. Rotation reduces irritation, lipodystrophy, scar tissue, and unpredictable absorption. Alternate left abdomen, right abdomen, left thigh, and right thigh when the compound does not require injury-adjacent placement. ### How do oral and injectable BPC-157 compare for injury recovery? No. Oral BPC-157, especially PDA-style formulations, is a gut-first route. It may have systemic downstream effects, but it is not the same exposure model as injectable BPC-157 near an injury. ### What about topical peptides? Topical GHK-Cu and AHK-Cu are relevant for skin and scalp. Topical use makes sense when the target is reachable from the surface. It does not replace injection for deep musculoskeletal targets. --- ## Related Topics - [Peptide Reconstitution Guide](/content/reconstitution) - Step-by-step reconstitution with BAC water - [Peptide Dosing Calculator](/tools/calculator) - Convert vial concentration to injection volume - [BPC-157 Guide](/content/bpc-157) - Complete mechanism, dosing, oral vs injectable - [TB-500 Guide](/content/tb-500) - TB-500 vs TB-4, fragment-specific mechanisms - [Wolverine Stack](/content/wolverine-stack) - BPC-157 + TB-4/TB-500 protocol for injury recovery - [Injury Recovery Protocol](/content/injury-recovery-peptide-protocol) - Full injury-recovery framework - [NAD+ Guide](/content/nad-guide) - Dosing, cycling, route, and injection comfort - [GHK-Cu Guide](/content/ghk-cu-skin) - Copper peptide for skin and tissue remodeling - [GLOW & KLOW Protocol](/content/glow-klow-protocol) - Cosmetic blend protocols - [GLOW & KLOW for Injuries](/tools/klow-dosage-calculator) - Same compounds, repaired ratios for injury work, plus per-compound injection-site logic - [GH Secretagogue Comparison](/content/gh-secretagogue-comparison) - Ipamorelin, tesamorelin, sermorelin, and older GHRPs - [Peptide Stacking Guide](/content/peptide-stacking-guide) - How compounds combine --- ## References ¹ **Subcutaneous absorption by molecular weight** - Molecules under roughly 16 kDa are absorbed primarily by diffusion into blood capillaries. Supersaxo A et al. *Pharm Res.* 1990;7(2):167-9. [PMID 2137911](https://pubmed.ncbi.nlm.nih.gov/2137911/) ² **Injection site pharmacokinetics** - Injection site can affect peptide and small-protein PK through regional blood flow and pre-systemic proteolysis. Zou P et al. *J Control Release.* 2021;336:425-445. [PMID 34186147](https://pubmed.ncbi.nlm.nih.gov/34186147/) ³ **BPC-157 repair signaling** - Review of musculoskeletal BPC-157 mechanisms and preclinical repair models. McGuire FP et al. *Curr Rev Musculoskelet Med.* 2025;18(12):611-619. [PMC12446177](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/) ⁴ **GHK-Cu gene expression and effective concentration** - GHK-Cu modulates broad repair and remodeling gene expression and is active at low nanomolar concentration. Pickart L, Margolina A. *Int J Mol Sci.* 2018. [PMC6073405](https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) ⁵ **TB-500 prodrug metabolism** - Active metabolite is Ac-LKKTE after serial C-terminal cleavage. Rahaman KA et al. *J Chromatogr B.* 2024;16(10):1248-1258. [PMID 38382158](https://pubmed.ncbi.nlm.nih.gov/38382158/) ⁶ **BPC-157 pharmacokinetics and tissue distribution** - Short half-life, tissue distribution, kidney enrichment, and skeletal-muscle concentration data. He L et al. *Front Pharmacol.* 2022. [PMC9794587](https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/) ⁷ **BPC-157 tendon signaling threshold** - Tendon fibroblast work using sustained higher concentrations to affect growth-hormone receptor expression. Chang CH et al. *J Appl Physiol.* 2014. [PMC6271067](https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/) ⁸ **BPC-157 tendon fibroblast migration** - In vitro tendon fibroblast migration work using sustained exposure. Staresinic M et al. *J Orthop Res.* 2003 / *J Appl Physiol.* 2011. [PMID 21030672](https://pubmed.ncbi.nlm.nih.gov/21030672/) ⁹ **GHK-Cu systemic healing from distant injection** - Review summarizing distant wound-healing effects from injected GHK/Cu complexes across animal models. Cushman CJ et al. *Yale J Biol Med.* 2024;97(3):399-413. [PMC11426299](https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/) ¹⁰ **BPC-157 human knee study and systematic review** - Lee & Padgett knee injection report summarized within a broader systematic review. Vasireddi N et al. *HSS J.* 2025. [PMC12313605](https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/) ¹¹ **BPC-157 literature review** - Broad review confirming the limited human route-comparison surface. Bauer 2025. [PMC11859134](https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/) ¹² **BPC-157 IP efficacy for MCL models** - Healing effects across routes in rat ligament injury models. Cerovecki T et al. *J Orthop Res.* 2010. [PMID 20225319](https://pubmed.ncbi.nlm.nih.gov/20225319/) ¹³ **BPC-157 muscle crush model** - IP and local cream effects in muscle injury. Novinscak T et al. *Surg Today.* 2008. [PMID 18668315](https://pubmed.ncbi.nlm.nih.gov/18668315/) ¹⁴ **BPC-157 with corticosteroid-impaired healing** - IP and local cream effects despite steroid-impaired healing. Staresinic M et al. *Med Sci Monit.* 2010. [PMID 20190676](https://pubmed.ncbi.nlm.nih.gov/20190676/) ¹⁵ **TB-4 biodistribution** - Urinary clearance and rapid blood-level decline after injection. Mora CA et al. *Int J Immunopharmacol.* 1997;19(1):1-8. [PMID 9226473](https://pubmed.ncbi.nlm.nih.gov/9226473/) ¹⁶ **Free systemic TB-4 vs targeted delivery** - Targeted nanoparticle delivery outperformed free systemic TB-4 in cardiac repair. Huang G et al. *Int J Nanomedicine.* 2017;12:3023-3036. [PMC5396927](https://pmc.ncbi.nlm.nih.gov/articles/PMC5396927/) ¹⁷ **Sustained local TB-4 release** - Scaffold-based local release improved wound closure in diabetic rats. Ti D et al. *Tissue Eng Part A.* 2015;21(3-4):541-549. [PMID 25204972](https://pubmed.ncbi.nlm.nih.gov/25204972/) ¹⁸ **Systemic TB-4 failure in pigs** - IV systemic TB-4 did not produce cardioprotection in a pig model. Stark C et al. *Front Pharmacol.* 2016. [Frontiers](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2016.00115/full) ¹⁹ **Tesamorelin injection-site reactions** - Phase III trial data report injection-site erythema, pruritus, and pain at clinically meaningful rates. Tesamorelin prescribing information. ²⁰ **NAD+ tissue uptake kinetics** - IV infusion study showing delayed plasma NAD+ rise consistent with rapid tissue uptake. Grant R et al. *Aging Cell.* 2019. ²¹ **SS-31 injection-site reactions** - TAZPOWER Phase III trial reports high rates of erythema, pruritus, and pain with daily SubQ elamipretide. ²² **Oral BPC-157 musculoskeletal model** - Oral BPC-157 produced quadriceps muscle-to-bone reattachment in rats. Matek D et al. 2025. [PMC11768438](https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/) ²³ **SS-31 MRGPRX2 mast-cell activation and mitigation** - Elamipretide is a direct MRGPRX2 agonist; topical mometasone reduced swelling without affecting absorption in a Phase 1 crossover study. *Fortune J Health Sci.* [Fortune Journals](https://www.fortunejournals.com/articles/interventions-with-potential-to-mitigate-injection-site-reactions-following-subcutaneous-elamipretide-administration-a-phase-1-cro.html) ²⁴ **KPV PepT1-dependent mechanism** - KPV suppresses inflammatory signaling in PepT1-expressing cells and lacks the same effect in cells without PepT1. Dalmasso G et al. *Gastroenterology.* 2008. [PMC2431115](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/) ²⁵ **Subcutaneous injection pain and local-reaction factors** - Needle geometry, injection depth, volume, speed, pH, and tonicity can influence pain and local reactions after SubQ administration. St Clair-Jones A et al. *Rheumatol Ther.* 2020;7:741-757. [PMC7672413](https://pmc.ncbi.nlm.nih.gov/articles/PMC7672413/) ²⁶ **EGRIFTA SV injection needle and labeled preparation** - The FDA-approved tesamorelin kit supplies a 1/2-inch, 30-gauge injection needle and specifies its supplied sterile water for reconstitution. [DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224) ²⁷ **MRGPRX2 recognition of cationic amphiphilic ligands** - Review of the receptor's ligand features and role in non-IgE mast-cell activation. [PMC8355064](https://pmc.ncbi.nlm.nih.gov/articles/PMC8355064/) ²⁸ **Cationic amphiphilic compounds and human wheal-and-flare** - Pharmacophore modeling and human skin-response evidence for MRGPRX2 activation. [PMID 33617860](https://pubmed.ncbi.nlm.nih.gov/33617860/) ²⁹ **NaCl and peptide self-assembly** - In an oxyntomodulin formulation model, NaCl screened charge repulsion and promoted reversible nanofibril assembly; it does not establish a universal beyond-use date. Ouberai MM et al. *Nat Commun.* 2017;8:1026. [DOI: 10.1038/s41467-017-01114-1](https://doi.org/10.1038/s41467-017-01114-1) ³⁰ **Therapeutic peptide formulation stability** - Review of pH, ionic strength, aggregation, and other formulation variables that affect peptide stability. [PMC10056213](https://pmc.ncbi.nlm.nih.gov/articles/PMC10056213/) ³¹ **Subcutaneous formulation factors** - Review of how pH, osmolality, concentration, volume, and other formulation attributes affect SubQ tolerability and absorption. [PMC6822791](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/) ³² **FoxAI formulation synthesis** - Diluent preferences without direct comparison studies, the conservative 7–14-day refrigerated window, and taurine's restriction to supplied formulations or written protocols are protocol guidance derived from formulation chemistry and field observation, not compound-specific trial results. *Educational only. Injection technique, sterile handling, and prescription medication use should be guided by a qualified clinician. Some compounds discussed here are prescription drugs, while many peptide-market uses are investigational, off-label, or community-derived.*